Fulminant hepatic failure secondary to erlotinib

Clin Gastroenterol Hepatol. 2007 Aug;5(8):917-20. doi: 10.1016/j.cgh.2007.04.014. Epub 2007 Jul 10.

Abstract

Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of non-small-cell lung cancer and pancreatic cancer. We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Aged
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / secondary
  • ErbB Receptors / antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Female
  • Humans
  • Liver Failure, Acute / chemically induced*
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects*
  • Quinazolines / administration & dosage
  • Quinazolines / adverse effects*

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors